Indigo Biosciences

Indigo Biosciences is a privately held provider of specialized in vitro assay kits and screening services, primarily serving the drug discovery and environmental toxicology markets. Founded in 2005 and headquartered in State College, Pennsylvania, the company has built a portfolio of proprietary, engineered reporter cell lines for targets in endocrine, metabolic, and neurological pathways. Its business model is based on selling assay kits directly to researchers and offering fee-for-service screening, positioning it as a tools and services company rather than a therapeutic developer. The company appears to be in a revenue-generating stage, supported by a steady stream of new product launches and a clear focus on niche target classes.

Proprietary engineered mammalian cell-based luciferase reporter assays for nuclear receptors, GPCRs, and other drug targets, enabling functional agonist/antagonist screening.

Indigo competes in the niche market for specialized reporter assay kits and services. Primary competitors include large public tools companies (e.g., Thermo Fisher, Revvity) with broad assay portfolios, as well as smaller private firms focusing on specific target classes. Differentiation is achieved through proprietary cell engineering, assay simplicity, and a focus on customer support in targeted applications like nuclear receptor and GPCR screening.